Shire’s $2.4 billion cancer-unit sale sweetens Takeda appeal
Bloomberg Shire Plc agreed to sell its cancer unit to France’s Servier SAS for $2.4 billion, tightening the US-based drugmaker’s focus on rare diseases and potentially making it more attractive to Takeda Pharmaceutical Co. as it considers a bid. The Shire unit sells treatments for leukemia and pancreatic cancer, the Lexington, Massachusetts-based company said in a statement on Monday. The ...
Read More »